CD8A and hepatocellular carcinoma: Anlotinib treatment inhibits the VEGFR2/AKT/HIF-1α signaling axis, reducing TRFC expression and increasing CXCL14 production in HCC, thereby mediating CD8+ T cells chemotaxis and enhancing the efficacy of anti-PD-1 in HCC[95].